Corporate Profile

Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

19 Oct '20
-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 -- -- Poster at Society for Immunotherapy of Cancer Annual Meeting evaluates   the

Featured Reports

More information is coming soon.